Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 9 February 1996:
Vol. 271. no. 5250, pp. 755 - 756
DOI: 10.1126/science.271.5250.755
Prev | Table of Contents | Next

News

Jon Cohen

Early clinical trials have indicated that a potential new class of AIDS drugs, known as the protease inhibitors, may both decrease the amount of HIV in patients' blood and possibly decrease disease and death by as much as 50%. Those findings, combined with others showing that people with lower viral loads fare better than people who have a lot of virus in their blood, have encouraged AIDS researchers, although given the previous ups and downs of the first AIDS drug, AZT, they remain cautious about the future prospects of the protease inhibitors.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Lamivudine-Zidovudine Treatment and Clinical End Points.
A. Schattner (1996)
JAMA 276, 1637
   Abstract »    PDF »
AIDS in 1996 Much Accomplished, Much to Do.
A. S. Fauci (1996)
JAMA 276, 155-156
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)